Reviewing Cadrenal Therapeutics (CVKD) & Its Rivals

Cadrenal Therapeutics (NASDAQ:CVKD) is one of 988 public companies in the “Pharmaceutical preparations” industry, but how does it weigh in compared to its rivals? We will compare Cadrenal Therapeutics to related businesses based on the strength of its earnings, valuation, institutional ownership, dividends, profitability, risk and analyst recommendations.

Insider and Institutional Ownership

7.9% of Cadrenal Therapeutics shares are owned by institutional investors. Comparatively, 44.8% of shares of all “Pharmaceutical preparations” companies are owned by institutional investors. 58.1% of Cadrenal Therapeutics shares are owned by insiders. Comparatively, 14.1% of shares of all “Pharmaceutical preparations” companies are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Volatility and Risk

Cadrenal Therapeutics has a beta of 1.15, meaning that its share price is 15% more volatile than the S&P 500. Comparatively, Cadrenal Therapeutics’ rivals have a beta of 0.85, meaning that their average share price is 15% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings and price targets for Cadrenal Therapeutics and its rivals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cadrenal Therapeutics	0	0	2	0	3.00
Cadrenal Therapeutics Competitors	6184	18552	44227	910	2.57

Cadrenal Therapeutics presently has a consensus price target of $3.50, suggesting a potential upside of 759.32%. As a group, “Pharmaceutical preparations” companies have a potential upside of 80.56%. Given Cadrenal Therapeutics’ stronger consensus rating and higher probable upside, equities analysts plainly believe Cadrenal Therapeutics is more favorable than its rivals.

Earnings and Valuation

This table compares Cadrenal Therapeutics and its rivals gross revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Cadrenal Therapeutics	N/A	-$8.36 million	-0.59
Cadrenal Therapeutics Competitors	$2.15 billion	$149.20 million	-4.23

Cadrenal Therapeutics’ rivals have higher revenue and earnings than Cadrenal Therapeutics. Cadrenal Therapeutics is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Profitability

This table compares Cadrenal Therapeutics and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Cadrenal Therapeutics	N/A	-128.67%	-117.76%
Cadrenal Therapeutics Competitors	-2,601.54%	-229.25%	-29.53%

Summary

Cadrenal Therapeutics beats its rivals on 8 of the 13 factors compared.

About Cadrenal Therapeutics

Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome. Cadrenal Therapeutics, Inc. was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.